Allergan (AGN) Slips Lower on FDA Generic Restasis Discussion
Tweet
Share
E-mailGet Alerts AGN Hot Sheet
Join SI Premium – FREE
Allergan (NYSE: AGN) is lower on Friday's session following a new FDA document which discusses generic cyclosporine ophthalmic emulsion (generic Restasis).
To read the full document (in pdf form), click here.
Shares pf Allergan are down 5.4 percent.
To read the full document (in pdf form), click here.
Shares pf Allergan are down 5.4 percent.
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
